BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AXSM upcoming catalysts

Axsome Therapeutics, Inc.: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 1 FDA event(s). Subscribe to AXSM (.ics).

Drugs: Solriamfetol

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2027-05-01PDUFA date (company-disclosed)pendingAxsome Therapeutics, Inc. AXSMPDUFA May 1, 2027 - Axsome Therapeutics, Inc.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Axsome Therapeutics, Inc. AXSMNCT06413433 Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolBinge-Eating Disorderrecruiting450
2026-12 est.P3Axsome Therapeutics, Inc. AXSMNCT06568367 Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Excessive Sleepiness; Shift-work Disorderrecruiting520

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-30FDA approvalapprovedAXSOME AXSMAUVELITYApproved 2026-04-30: AUVELITY (NDA215430 SUPPL18)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.